Switching from Vumerity to Tecfidera: Monitoring and Management

Laboratory Monitoring

• The American Academy of Dermatology recommends continued regular laboratory monitoring as recommended for fumarate therapies, including urinalysis and serum chemistry profile, every 2 weeks for the first month, monthly for the first 6 months, and bimonthly thereafter 1

Managing Side Effects

• Flushing may occur in approximately one-third of patients, according to the Journal of the American Academy of Dermatology 2
• Management strategies for increased side effects include taking medication with food to reduce GI symptoms 1
• Temporary dose reduction may be considered if symptoms are severe, as suggested by the Journal of the American Academy of Dermatology 2
• Symptomatic medications may be needed, and lymphopenia monitoring should continue, as recommended by the Journal of the American Academy of Dermatology 2